Share This

Related Topics News -

     
 Detail   |   Print    Next page > 
     
科濟藥業-B旗下兩項藥品摘要將於歐洲進行口頭報告及壁報展示
2024-04-30T  
科濟藥業-B已向美國FDA提交糾正和預防措施計劃整改報告
2024-04-29T  
科濟藥業於醫學年會報告癌症藥物試驗數據
2024-04-12T  
《公司業績》科濟藥業全年虧損收窄至7.48億人民幣
2024-03-27T  
科濟藥業-B:藥監局批准「賽愷澤」新藥上市申請
2024-03-01T  
科濟藥業-B治療胃癌藥物臨床試驗安全性令人鼓舞
2024-01-19T  
科濟藥業-B治療肝細胞癌新藥獲內地IND批准
2024-01-15T  
科濟藥業-B主要股東益傑生物擬增持不逾2%股份
2023-12-18T  
科濟藥業-B(02171.HK)曾瀉36%破底 旗下藥物被美國監管當局叫停臨床試驗
2023-12-13T  
科濟藥業(02171.HK)在美臨床試驗因CMC問題被叫停
2023-12-13T  
  Next page > 

Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map
Copyright (C) 2024 Suntek Computer Systems Limited. All rights reserved
Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.